| Health indices for disease incidence and duration in the semi-markov setting A Soetewey, C Legrand, M Denuit, G Silversmit Technical report, Université catholique de Louvain, Institute of Statistics …, 2024 | 1 | 2024 |
| Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data Q Le Coënt, C Legrand, V Rondeau Biostatistics 25 (1), 98-116, 2024 | 3 | 2024 |
| Right to be forgotten for mortgage insurance issued to cancer survivors: critical assessment and new proposal A Soetewey, C Legrand, M Denuit, G Silversmit LIDAM Discussion Papers ISBA, 2023 | 1 | 2023 |
| Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations E Seront, A Van Damme, C Legrand, A Bisdorff-Bresson, P Orcel, ... JCI insight 8 (21), 2023 | 8 | 2023 |
| Evaluation of primary care physicians' competence in selective skin tumour triage after short versus long dermoscopy training: a randomized non‐inferiority trial E Harkemanne, C Legrand, K Sawadogo, A van Maanen, K Vossaert, ... Journal of the European Academy of Dermatology and Venereology 37 (8), 1595-1605, 2023 | 5 | 2023 |
| On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes M De Backer, C Legrand, J Péron, A Lambert, M Buyse Pharmaceutical Statistics 22 (2), 284-299, 2023 | 2 | 2023 |
| Semi-markov modeling for cancer insurance A Soetewey, C Legrand, M Denuit, G Silversmit European Actuarial Journal 12 (2), 813-837, 2022 | 8 | 2022 |
| Focus 29-mars 2022: Le développement des vaccins anti-Covid-19 est-il allé trop vite? C Legrand, S Tubeuf Regards économiques, 2022 | | 2022 |
| Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long‐term clinical endpoint L Garcia Barrado, T Burzykowski, C Legrand, M Buyse Pharmaceutical Statistics 21 (1), 209-219, 2022 | 3 | 2022 |
| Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial J Declercq, KFA Van Damme, E De Leeuw, B Maes, C Bosteels, ... The Lancet Respiratory Medicine 9 (12), 1427-1438, 2021 | 111 | 2021 |
| Années de vie perdues appliquées aux contrats d’assurance à horizon fini pour les patients cancéreux A Soetewey, C Legrand, M Denuit Age 4 (6), 8, 2021 | | 2021 |
| Waiting period from diagnosis for mortgage insurance issued to cancer survivors A Soetewey, C Legrand, M Denuit, G Silversmit European Actuarial Journal 11 (1), 135-160, 2021 | 4 | 2021 |
| Advanced survival models C Legrand Chapman and Hall/CRC, 2021 | 25 | 2021 |
| A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons E Cantagallo, M De Backer, M Kicinski, B Ozenne, L Collette, C Legrand, ... Biometrical Journal 63 (2), 272-288, 2021 | 6 | 2021 |
| Package ‘miCoPTCM’ A Bertrand, C Legrand, I Van Keilegom, MA Bertrand, M Imports | | 2020 |
| Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country G Molenberghs, M Buyse, S Abrams, N Hens, P Beutels, C Faes, ... Contemporary Clinical Trials 99, 106189, 2020 | 23 | 2020 |
| Joint longitudinal and time-to-event cure models for the assessment of being cured A Barbieri, C Legrand Statistical methods in medical research 29 (4), 1256-1270, 2020 | 8 | 2020 |
| Les experts de l'UCLouvain vous répondent:" Plusieurs indicateurs nécessaires pour une épidémie" N Speybroeck, C Legrand Le Vif-L'Express, 2020 | | 2020 |
| Evaluating case management as a complex intervention: Lessons for the future AS Lambert, C Legrand, S Cès, T Van Durme, J Macq PLoS One 14 (10), e0224286, 2019 | 19 | 2019 |
| DNA alteration‐based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in high‐risk group D Narasimhaiah, C Legrand, D Damotte, R Remark, M Munda, ... Cancer medicine 8 (6), 3036-3046, 2019 | 13 | 2019 |
